Diabetes Therapy
Biphasic insulin aspart 30 maintains postprandial BG better than traditional insulin
Published in Obesity and Diabetes Week, February 13th, 2006
"Major advantages of modern insulin regimens containing premixed insulin analogues in comparison to traditional insulin regimens have not been evaluated yet. The aim of the present study was to investigate whether meal-related (breakfast, lunch, dinner) application of biphasic insulin aspart 30 (BIAsp 30) provides better glycemic control than administration of biphasic human insulin 30 (BHI 30) twice per day," scientists writing in the journal Hormone and Metabolic Research report.
H. Abrahamian and colleagues...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Pathogenesis
Improved insulin resistance after weight loss is not linked to adiponectin changes - Diet & Nutrition
Long-chain polyunsaturated fatty acid diet may protect obese against metabolic syndrome - Drug Safety
Orlistat and micronized fenofibrate are safe and effective for overweight and obese - Obesity Therapy
(+)-Z-BDDA may have applications in treating obesity and metabolic syndrome complications - Type 2 Diabetes
Vaspin expression in adipose tissue may be linked to obesity and type 2 diabetes - Anesthesia
Anesthesia can cause sustained hyperglycemia in C57/BL6J mice - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
